Meitu Financial Report: In 2023, investments in Bitcoin and Ethereum incurred losses of 170 million yuan and 94.8 million yuan respectively
Meitu recently disclosed its 2023 performance, achieving a revenue of about 2.696 billion yuan, an increase of 29.27% year-on-year; the adjusted net profit attributable to the parent company was 370 million yuan (excluding the impact of cryptocurrency depreciation and other factors), an increase of 233.2% year-on-year. However, Meitu still suffered losses in cryptocurrency investments. In 2023, Meitu's investments in Bitcoin and Ethereum respectively lost 170 million yuan and 94.8 million yuan, while in 2022 they respectively lost 198.2 million yuan and 86.6 million yuan. Meitu stated that the growth in total revenue and net profit is mainly due to AI driving the growth of main business income.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
BNP Paribas gives Microsoft (MSFT.US) a "Buy" rating: Azure price increases will be gradually implemented after contract renewals, and a deal with SpaceX may be announced soon.
BNP Paribas has rated Microsoft as "Buy" with a target price of $549.
Iranian President will head to New York for UN meeting
"Big Short" Burry opens a position in QXO (QXO.US), betting on building products integration and undervaluation; stock price rises over 7%
Investor Michael Burry disclosed that he has purchased common and preferred shares of QXO (QXO.US), a building products company, citing its integration strategy and the currently depressed stock price. The stock surged 7.2% on Monday.
700,000 new elderly patients join, Eli Lilly (LLY.US) dominates 70%: The first Medicare weight loss drug coverage report released
Dave Ricks, CEO of Eli Lilly (LLY.US), said in an interview on Monday that since Medicare began coverage for obesity drugs in July, 700,000 new elderly patients have started using GLP-1 medications.